BPI-585725 / Betta Pharma - LARVOL DELTA

KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models (AACR 2025) - "In multiple KRAS driven CDX models, weekly dosing of BPI-585725 dose dependently inhibited the tumor growth. In conclusion BPI-585725 is a highly potent and selective KRASmulti degrader with favorable pharmacokinetic properties, demonstrating a promising safety in preclinical studies."

Preclinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • DUSP6 • HRAS • KRAS